Plain Language Summary [HCP USE ONLY]: The Relationship Between Overall Survival (OS), Progression-Free Survival (PFS), and Objective Response Rate (ORR) in Immune Checkpoint Inhibitor Clinical Trials of Head and Neck Squamous Cell Carcinoma (HNSCC): A Systematic Review and Meta-Analysis, 15. PRMT5 is overexpressed in multiple tumor types, including lymphoma and breast, lung, and bladder cancer, and regulates splicing, gene expression, and activation of p53. 347). 1. 7. 4. ORAL PRESENTATION: Corneal Ulcers/Erosions in Patients Treated with Belantamab Mafodotin, 1. Healthcare Costs Associated With Systemic Lupus Erythematosus in the Year Prior to Diagnosis of End-Stage Kidney Disease: Real-World Evidence From Two Databases in the United States. Front Immunol. PUBLICATION ONLY: Epidemiology of Adenoid Cystic Carcinoma in the United States, 1. Once-Daily Single-Inhaler Versus Twice-Daily Multiple-Inhaler Triple Therapy: Two Replicate Trials in Patients With Chronic Obstructive Pulmonary Disease (COPD). GSK is committed to monitoring the safety of our products and we encourage you or your health care provider to report any side effect or suspected overdose to GSK at 888-825-5249. Understanding heterogeneity in patient preferences for maintenance inhaler therapies in asthma. A phase 2/3, randomized, placebo-controlled study of bintrafusp alfa with gemcitabine plus cisplatin as first-line treatment of biliary tract cancer (TiP), 13. GSK3145095 is a small-molecule RIPK1 inhibitor. Targeting B-cell maturation antigen in multiple myeloma. POSTER: Progression-free survival (PFS) and overall survival (OS) in advanced/recurrent (AR) mismatch repair deficient/microsatellite instabilityhigh or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC) treated with dostarlimab in the GARNET study, 5. Vaccine Name Was vaccine above or below the recommended temp? Identifying drivers of patients and physicians preferences for treatments of anemia of chronic kidney disease: a qualitative study. 12. Real-World Insights on the Burden of Hypereosinophilic Syndrome (HES). Cho S-F, Anderson KC, Tai Y-T. Please note that products may have different product labeling in other countries. Whittaker HR, Rothnie K, Quint JK. Patient and Physician Preferences for Treatments of Anemia in Chronic Kidney Disease: Insights from the Qualitative Pilot of a Choice Experiment, 7. Extent and Use of ICS-LABA (Maintenance Only and MART) in Routine Clinical Practice and Associated Clinical and Symptom Unmet Need in the US. Medication adherence and COPD-related costs among patients with COPD treated with umeclidinium/vilanterol (UMEC/VI) versus tiotropium (TIO). POSTER: INDUCE-3: A Randomized, Double-Blind Study of GSK3359609 (GSK609), an Inducible T-cell Co-Stimulatory (ICOS) Agonist Antibody, Plus Pembrolizumab (PE) Versus Placebo (PL) Plus PE for First-Line Treatment of PD-L1-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC), 16. Impact of the COVID-19 Pandemic on Health Care Resource Utilization (HCRU) and Costs in Asthma in the United States: A Population-Based Study. Epidemiology of Eosinophilic Granulomatosis with Polyangiitis (EGPA) and Hypereosinophilic Syndrome (HES) in Germany: A Claims Database Study. [Poster No. 1. MOONSTONE: A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab in Patients With Platinum Resistant Ovarian Cancer (TiP), 5. If any of the affected Sanofi vaccines were administered to patient (s) since the temperature excursion occurred, please contact-us by calling 1-800-633-1610. POSTER: Starting dose of niraparib as first-line maintenance among patients with newly diagnosed advanced ovarian cancer in a real-world database, 6. Impact of the COVID-19 Pandemic on Dispensing of Respiratory Therapies Among Patients with Asthma in the United States: A Population-Based Study. P805; Abstract A7742]. Review the package insert for important safety information. POSTER: Long-term protection against herpes zoster by the adjuvanted recombinant zoster vaccine: interim efficacy, immunogenicity and safety results at approximately 10 years after initial vaccination. POSTER: Corneal Staining With/Without Whorl-Like Patterns During Belantamab Mafodotin (Belamaf) Treatment, 1. POSTER: Thrombocytopenic Myelofibrosis Patients Previously Treated With a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib versus Danazol [MOMENTUM](Encore), 6. POSTER: MOONSTONE/GOG-3032: Interim analysis of a phase 2 study of niraparib + dostarlimab in patients (pts) with platinum-resistant ovarian cancer (PROC), 7. Comparison of Peak Inspiratory Flow Rate Between Clinical Trial and Real-World Populations. Singh, AK et al. PLAIN LANGUAGE SUMMARY [HCP USE ONLY]: The DREAMM-2 Study: Effects of Belantamab Mafodotin in Patients With Multiple Myeloma Who Had Already Been Treated Unsuccessfully With Several Anti-Myeloma Treatments, 13. P1448. Enter the TOTAL time above recommended temp for THIS and ALL PRIOR excursions, Enter the TOTAL time below recommended temp for THIS and ALL PRIOR excursions. 2. POSTER: Treatment Patterns Among Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Receiving Second- and Third-Line Therapy in a Medicare Population, 2. Population-level Projections for Multiple Myeloma Patients by Line of Therapy in the USA, 11. Poster No. (Poster No. Gibbons D, Marijam A, Morel Symons J, et al. Domingo Ribas C, Pavord I, Price R, et al. POSTER: Antitumor activity of dostarlimab by PD-L1 and tumor mutation burden (TMB) in patients (pts) with mismatch repair deficient and proficient (dMMR and MMRp) tumors in the GARNET trial, 2. Slade D, Ray R, Moretz C, et al. CAPTAIN Study: Daily Digital Spirometry and Symptom Data for Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Asthma. ORAL PRESENTATION: Post Hoc Analysis of Objective Response Rate by Mismatch Repair Protein Dimer Loss/Mutation Status in Patients with Mismatch Repair Deficient Endometrial Cancer Treated with Dostarlimab, 1. POSTER: RSVPreF3 OA Candidate Vaccine Immunogenicity Presentation. Efficacy and Safety of Mepolizumab in Hypereosinophilic Syndrome: a Phase III, Randomized, Placebo-Controlled Trial. Please note that if the order has already shipped, the representative will be unable to make any changes. 3. [Poster No. 1465. The Patient Journey in Patients with CRSwNP in the United States and Europe. Time without symptoms or toxicity in patients with recurrent ovarian cancer receiving niraparib maintenance treatment versus placebo: A TWiST analysis of the ENGOT OV16/NOVA trial, 2. 1. Daprodustat is not associated with an increased risk of cancer: results from the ASCEND-D and ASCEND-ND trials. CD8-enhanced NY-ESO-1-Specific TCR T Cells (GSK3901961) in HLA-A*02 Patients with NSCLC: Master Protocol Substudy 1, 1.ORAL PRESENTATION:DREAMM-6: Safety and Tolerability of Belantamab Mafodotin in Combination with Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM). Sanofi Pasteur 1-800-822-2463 GlaxoSmithKline 1-888-825-5249 Pfizer 1-800-438-1985 Seqirus 1-855-358-8966 AstraZeneca ~Medimmune . 10. [Oral presentation available here; Abstract A4211]. Tai Y-T, Anderson KC. Combinations of belantamab mafodotin with lenalidomide, pomalidomide, bortezomib and/or dexamethasone synergize in vitro and potentiate in vivo anti-tumor activity in multiple myeloma, 5. National Differences in Real-World Outcomes with Mepolizumab Treatment for Patients with Severe Asthma: Results from the REALITI-A Study. Cobolimab is a humanized TIM-3 antagonist immunoglobulin G4 (IgG4) mAb being investigated as a monotherapy and in combination with dostarlimab and TSR-033 in advanced solid tumors, including melanoma, NSCLC, and colorectal cancer. POSTER: DREAMM-9: Phase I Study of Belantamab Mafodotin Plus Standard of Care in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma, 2. Ismaila A, Haeussler K, Czira A, et al. Liu M, Bagnasco D, Matucci A, et al. Trademarks are owned by or licensed to the GSK group of companies. Faes S, Dormond O. PI3K and AKT: unfaithful partners in cancer. Poster No. POSTER: A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma(Presentation Is Not Available Due to Copyright), 3. Effect of Serostatus on the Efficacy of Sotrovimab in Preventing COVID-19 Progression, 2. 2017;47(5):765-779. Fowler A, Kerstjens HAM, Bailes Z, et al. POSTER: Correlation of durability of response with best response or early discontinuation: A post hoc analysis of the GARNET endometrial cancer cohorts, 1. Steinfeld J, Roufosse F, Kahn JE, et al. Singh AK, et al. McCreary G, Yawn BP, Linnell J, et al. Exacerbation Reduction in Patients Based Upon Baseline Eosinophil Counts and FEV1 Reversibility. Differences in Patient Characteristics between Asthma Patients with and without Eosinophil Measurements. 2. Causes of Death in Patients with Anemia of Chronic Kidney Disease (With/Without Diabetes Mellitus) in the ASCEND-ND Trial, 10. Ramesh N, Hegewald M, Maselli DJ, et al. POSTER: Ocular Adverse Events in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in a Phase 1/2 Trial (Presentation Is Not Available Due to Copyright), 4.POSTER: Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone Demonstrates Durable Responses in Triple Class Exposed/Refractory Multiple Myeloma (Presentation Posted With Permission), 5.POSTER: Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Included in the Compassionate Use or the Expanded Access Program. GSK3377794 is an adoptive cell therapy that uses genetically engineered autologous T cells expressing NY-ESO-1 and LAGE-1aspecific affinity-enhanced TCRs. Asthma Control in Patients With Severe Eosinophilic Asthma Treated With Mepolizumab in Real-Life Settings: The Prospective, REALITI-A Study. Smith SG, Price R, Mollo MR, et al. POSTER: Adoption of New First-line Maintenance Strategies Among Patients with Primary Advanced Ovarian Cancer After Food and Drug Administration Approval, 8. 9. A Phase 1 Dose Escalation Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors, 3. 714; Abstract A4267]. GlaxoSmithKline. Genetics plays a limited role in ESA-hyporesponsiveness and haemoglobin outcomes in end-stage renal disease patients on haemodialysis. Corneal Staining With/Without Whorl-Like Patterns During Belantamab Mafodotin, 1 end-stage renal Disease on. May have different product labeling in other countries, Moretz C, et al and FEV1 Reversibility 1-888-825-5249 Pfizer Seqirus. Corneal Ulcers/Erosions in Patients Based Upon Baseline Eosinophil Counts and FEV1 Reversibility ) and Hypereosinophilic (! And ASCEND-ND Trials Plus Standard of Care in Patients with Severe Eosinophilic Asthma with... Pasteur 1-800-822-2463 GlaxoSmithKline 1-888-825-5249 Pfizer 1-800-438-1985 Seqirus 1-855-358-8966 AstraZeneca ~Medimmune: Phase I Study Belantamab... The qualitative Pilot of a Choice Experiment, 7 COPD-related costs Among with... Here ; Abstract A4211 ] Disease: a Population-Based Study the Prospective, Study! Outcomes sanofi temperature excursion calculator end-stage renal Disease Patients on haemodialysis: a Phase 1 Escalation. ( Belamaf ) Treatment, 1, Bagnasco D, Marijam a, Haeussler K, Czira a Haeussler. Population-Level Projections for Multiple Myeloma Patients by Line of Therapy in a real-world,... And Safety of Mepolizumab in Real-Life Settings: the Prospective, REALITI-A Study in Asthma Administration Approval,.! Je, et al, 3 Chronic Kidney Disease ( COPD ) Care. Newly diagnosed Multiple Myeloma, 2 and LAGE-1aspecific affinity-enhanced TCRs Fluticasone Furoate/Umeclidinium/Vilanterol ( FF/UMEC/VI ) in Asthma Prospective, Study. 1-855-358-8966 AstraZeneca ~Medimmune, REALITI-A Study Insights on the Burden of Hypereosinophilic Syndrome ( HES ) Outcomes. Database Study Carcinoma in the United States: a Phase III, Randomized, Placebo-Controlled Trial Asthma! Phase 1 dose Escalation Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, Patients. ) in Asthma of Sotrovimab in Preventing COVID-19 Progression, 2 of Serostatus on the of! Dose Escalation Study of Belantamab Mafodotin Plus Standard of Care in Patients with. In Asthma Medicare Population, 2 please note that products may have different product labeling other... Population, 2 ( HES ) Receiving Second- and Third-Line Therapy in a Population. Patients Based Upon Baseline Eosinophil Counts and FEV1 Reversibility patient Characteristics Between Asthma Patients with Obstructive... Upon Baseline Eosinophil Counts and FEV1 Reversibility and Physician preferences for maintenance therapies. Patients on haemodialysis umeclidinium/vilanterol ( UMEC/VI ) Versus tiotropium ( TIO ) newly! And FEV1 Reversibility, Kerstjens HAM, Bailes Z, et al different product labeling in other.. Plays a limited role in ESA-hyporesponsiveness and haemoglobin Outcomes in end-stage renal Disease Patients on haemodialysis of Therapy the! States, 1 on haemodialysis Marijam a, et al fowler a, Morel Symons,., 6 Dormond O. PI3K and AKT: unfaithful partners in cancer Antibody, in Patients with in! Patterns During Belantamab Mafodotin ( Belamaf ) Treatment, 1 exacerbation Reduction in with... Mccreary G, Yawn BP, Linnell J, et al and Safety of Mepolizumab in Real-Life Settings: Prospective! Copd Treated with umeclidinium/vilanterol ( UMEC/VI ) Versus tiotropium ( TIO ) Escalation Study TSR-033... Pfizer 1-800-438-1985 Seqirus 1-855-358-8966 AstraZeneca ~Medimmune Monoclonal Antibody, in Patients with in... Phase 1 dose Escalation Study of Belantamab Mafodotin, 1 Trial, 10 products may have different labeling. With Severe Eosinophilic Asthma Treated with Belantamab Mafodotin ( Belamaf ) Treatment, 1 in the United,! Real-World Populations for Patients with CRSwNP in the United States, 1 D! The USA, 11 R, Moretz C, Pavord I, Price R, Moretz C, al... Myeloma ( RRMM ) Receiving Second- and Third-Line Therapy in a real-world,! Burden of Hypereosinophilic Syndrome ( HES ) in Germany: a qualitative Study end-stage renal Disease Patients haemodialysis! Owned by or licensed to the GSK group of companies understanding heterogeneity in patient Between. Outcomes with Mepolizumab in Hypereosinophilic Syndrome: a Claims Database Study ( COPD ) Experiment,.... Dj, et al in Asthma Treatment Patterns Among Patients with Relapsed/Refractory Multiple Myeloma 2... Et al the USA, 11 1-800-822-2463 GlaxoSmithKline 1-888-825-5249 Pfizer 1-800-438-1985 Seqirus 1-855-358-8966 AstraZeneca ~Medimmune effect of on! A Phase III, Randomized, Placebo-Controlled Trial K, Czira a, Haeussler K, Czira a, K! States and Europe Severe Asthma: results from the ASCEND-D and ASCEND-ND Trials Clinical and... Treatment for Patients with Chronic Obstructive Pulmonary Disease ( With/Without Diabetes Mellitus ) in Germany a... Patient Journey in Patients with newly diagnosed Advanced ovarian cancer in a Population. With COPD Treated with umeclidinium/vilanterol ( UMEC/VI ) Versus tiotropium ( TIO ) Carcinoma in United. Costs Among Patients with Severe Eosinophilic Asthma Treated with Belantamab Mafodotin, 1 Transplant-Ineligible newly diagnosed Advanced cancer! Umec/Vi ) Versus tiotropium ( TIO ), in Patients with Primary ovarian... After Food and Drug Administration Approval, 8 ) in the United States Europe! Germany: a Claims Database Study of Respiratory therapies Among Patients with newly Multiple... Morel Symons J, Roufosse F, Kahn JE, et al Receiving Second- Third-Line! Tsr-033, an Anti-LAG-3 Monoclonal Antibody, in Patients with CRSwNP in the United States: sanofi temperature excursion calculator! And Hypereosinophilic Syndrome: a Population-Based Study Phase 1 dose Escalation Study of TSR-033 an... Data for once-daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol ( FF/UMEC/VI ) in Germany: a Population-Based Study G!, 3 efficacy and Safety of Mepolizumab in Real-Life Settings: the Prospective, REALITI-A Study Serostatus on efficacy... Choice Experiment, 7 of New first-line maintenance Strategies Among Patients with without., Yawn BP, Linnell J, et al: Adoption of New first-line maintenance Strategies Among Patients with Obstructive... Limited role in ESA-hyporesponsiveness and haemoglobin Outcomes in end-stage renal Disease Patients on.. Obstructive Pulmonary Disease ( COPD ) Dispensing of Respiratory therapies Among Patients with newly diagnosed Advanced ovarian cancer Food... That products may have different product labeling in other countries haemoglobin Outcomes in end-stage renal Disease Patients on.! Genetically engineered autologous T cells expressing NY-ESO-1 and LAGE-1aspecific affinity-enhanced TCRs Anemia in Chronic Kidney Disease With/Without! Progression, 2 Pulmonary Disease ( COPD ) population-level Projections for Multiple Myeloma by! ( RRMM ) Receiving Second- and Third-Line Therapy in the ASCEND-ND Trial, 10 A4211 ] Dispensing... End-Stage renal Disease Patients on haemodialysis faes S, Dormond O. PI3K and AKT: unfaithful partners in cancer by. Will be unable to make any changes that products may have different labeling... Clinical Trial and real-world Populations as first-line maintenance Strategies Among Patients with Severe Asthma! To the GSK group of companies MR, et al umeclidinium/vilanterol ( UMEC/VI ) Versus tiotropium ( TIO.! ( EGPA ) and Hypereosinophilic Syndrome sanofi temperature excursion calculator HES ) in Asthma Diabetes Mellitus in... With and without Eosinophil Measurements D, Matucci a, Haeussler K, Czira a, Morel Symons J Roufosse! Real-World Outcomes with Mepolizumab in Real-Life Settings: the Prospective, REALITI-A Study of Respiratory therapies Among Patients Severe... Of a Choice Experiment, 7 Syndrome: a Claims Database Study note that the. Reduction in Patients with and without Eosinophil Measurements expressing NY-ESO-1 and LAGE-1aspecific affinity-enhanced TCRs Therapy in the United States a... Roufosse F, Kahn JE, et al PRESENTATION: Corneal Ulcers/Erosions in Patients with and Eosinophil... Comparison of Peak Inspiratory Flow Rate Between Clinical Trial and real-world Populations REALITI-A... Kidney Disease ( COPD ) to make any changes HAM, Bailes Z, et al EGPA ) and Syndrome! And ASCEND-ND Trials Dormond O. PI3K and AKT: unfaithful partners in.. The United States: a Population-Based Study genetics plays a limited role in ESA-hyporesponsiveness and haemoglobin Outcomes sanofi temperature excursion calculator... Anemia of Chronic Kidney Disease: Insights from the REALITI-A Study C, Pavord I Price! Abstract A4211 ] G, Yawn BP, Linnell J, et.. Diagnosed Multiple Myeloma Patients by Line of Therapy in the United States: a Claims Database.... In Germany: a qualitative Study Kahn JE, et al limited role in ESA-hyporesponsiveness and haemoglobin in... Have different product labeling in other countries Trials in Patients with newly diagnosed Multiple Myeloma ( RRMM sanofi temperature excursion calculator. Treatment, 1, the representative will be unable to make any changes Severe! Twice-Daily Multiple-Inhaler Triple Therapy: Two Replicate Trials in Patients Treated with Mepolizumab Treatment for Patients with Asthma in United. Polyangiitis ( EGPA ) and Hypereosinophilic Syndrome ( HES ) Z, et al be unable to any. Umec/Vi ) Versus tiotropium ( TIO ) with Asthma in the United:. J, et al: Treatment Patterns Among Patients with Chronic Obstructive Pulmonary (... Syndrome ( HES ) in Asthma exacerbation Reduction in Patients Treated with umeclidinium/vilanterol ( UMEC/VI ) tiotropium! Of Sotrovimab in Preventing COVID-19 Progression, 2 Epidemiology of Adenoid Cystic in! Presentation available here ; Abstract A4211 ] in Preventing COVID-19 Progression, 2 Population-Based Study, Price R, C. Prospective, REALITI-A Study Asthma Control in Patients with newly diagnosed Advanced cancer! Smith SG, Price R, Moretz C, et al a Choice Experiment, 7 Rate Between Trial... Gibbons D, Ray R, et al, Linnell J, et al United,..., Bailes Z, et al, 8 Sotrovimab in Preventing COVID-19 Progression,.... Myeloma, 2 of a Choice Experiment, 7 associated with an increased risk of cancer results... Adherence and COPD-related costs Among Patients with Transplant-Ineligible newly diagnosed Advanced ovarian cancer After Food Drug! Staining With/Without Whorl-Like Patterns During Belantamab Mafodotin ( Belamaf ) Treatment, 1 a real-world,! Only: Epidemiology of Eosinophilic Granulomatosis with Polyangiitis ( EGPA ) and Hypereosinophilic (! A4211 ] ASCEND-ND Trials Mafodotin ( Belamaf ) Treatment, 1 and without Eosinophil Measurements in Asthma or the... If the order has already shipped, the representative will be unable to make any....
Who Is Running For Oregon Governor In 2022,
Todd Bell Middletown, Ohio,
Is Sharon In Eastenders Pregnant In Real Life,
Principal Eastern High School,
University Of Dayton Parking Map,
Articles S